Bank of Nova Scotia
ALNY icon

Bank of Nova Scotia’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bank of Nova Scotia’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.45M Buy
8,130
+332
+4% +$100K ﹤0.01% 747
2026
Q1 		$2.58M Buy
7,798
+49
+0.6% +$16.7K ﹤0.01% 698
2025
Q4 		$3.08M Buy
7,749
+1,805
+30% +$799K ﹤0.01% 718
2025
Q3 		$2.71M Buy
5,944
+3,265
+122% +$1.33M ﹤0.01% 656
2025
Q2 		$874K Sell
2,679
-1,827
-41% -$506K ﹤0.01% 790
2025
Q1 		$1.22M Sell
4,506
-6
-0.1% -$1.54K ﹤0.01% 712
2024
Q4 		$1.06M Sell
4,512
-1,971
-30% -$518K ﹤0.01% 776
2024
Q3 		$1.78M Sell
6,483
-151
-2% -$39.3K ﹤0.01% 677
2024
Q2 		$1.61M Sell
6,634
-6,729
-50% -$1.06M ﹤0.01% 696
2024
Q1 		$2M Buy
13,363
+7,338
+122% +$1.22M ﹤0.01% 657
2023
Q4 		$1.15M Buy
6,025
+3,077
+104% +$524K ﹤0.01% 755
2023
Q3 		$522K Buy
2,948
+457
+18% +$87.2K ﹤0.01% 791
2023
Q2 		$473K Sell
2,491
-760
-23% -$151K ﹤0.01% 830
2023
Q1 		$651K Sell
3,251
-1,160
-26% -$244K ﹤0.01% 794
2022
Q4 		$1.05M Buy
4,411
+1,004
+29% +$214K ﹤0.01% 802
2022
Q3 		$682K Buy
3,407
+813
+31% +$155K ﹤0.01% 900
2022
Q2 		$378K Sell
2,594
-4,569
-64% -$648K ﹤0.01% 1059
2022
Q1 		$1.17M Buy
7,163
+5,699
+389% +$868K ﹤0.01% 893
2021
Q4 		$249K Buy
+1,464
New +$272K ﹤0.01% 1167
2021
Q2 		– Sell
-3,110
Closed -$439K – 1067
2021
Q1 		$439K Sell
3,110
-1,291
-29% -$194K ﹤0.01% 968
2020
Q4 		$572K Buy
4,401
+146
+3% +$19.5K ﹤0.01% 872
2020
Q3 		$620K Buy
4,255
+515
+14% +$73.2K ﹤0.01% 821
2020
Q2 		$554K Buy
+3,740
New +$504K ﹤0.01% 722
2019
Q3 		– Sell
-43,790
Closed -$3.18M – 896
2019
Q2 		$3.18M Buy
43,790
+9,790
+29% +$751K 0.01% 511
2019
Q1 		$3.18M Sell
34,000
-140,000
-80% -$11.7M 0.01% 533
2018
Q4 		$12.7M Buy
+174,000
New +$13.4M 0.06% 243

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of Nova Scotia's ALNY Position: Q2 2026 in Review

Bank of Nova Scotia increased its Alnylam Pharmaceuticals (ALNY) stake by 4.3% in Q2 2026, buying an estimated $100K and bringing the position to 8,130 shares worth $2.45M. The position accounts for ﹤0.01% of the portfolio, ranked #747.

Bank of Nova Scotia first reported a position in ALNY in Q4 2018 and has held it in 26 quarters since. The position peaked at $12.7M in Q4 2018. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Bank of Nova Scotia held 8,130 shares of Alnylam Pharmaceuticals worth $2.45M as of Q2 2026.
  • Bank of Nova Scotia bought 332 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $100K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Bank of Nova Scotia's portfolio in Q2 2026, its #747 holding.
  • Bank of Nova Scotia first reported a position in Alnylam Pharmaceuticals in Q4 2018 and has held it in 26 quarters since.
  • Bank of Nova Scotia's Alnylam Pharmaceuticals position peaked at $12.7M in Q4 2018.
  • 785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Bank of Nova Scotia's 13F filing for Q2 2026, filed 12 Aug 2026.